Complementary Predictors for Asthma Attack Prediction in Children: Salivary Microbiome, Serum Inflammatory Mediators, and Past Attack History
- PMID: 40823900
- DOI: 10.1111/all.70004
Complementary Predictors for Asthma Attack Prediction in Children: Salivary Microbiome, Serum Inflammatory Mediators, and Past Attack History
Abstract
Background: Early identification of children at risk of asthma attacks is important for optimizing treatment strategies. We aimed to integrate salivary microbiome and serum inflammatory mediator profiles with asthma attacks history to develop a comprehensive predictive model for future attacks.
Methods: This study contained a discovery (SysPharmPediA) and a replication phase (U-BIOPRED). School-aged children with asthma were classified into at risk and no-risk groups, based on the presence or absence of one or more severe attacks during one-year follow-up. Prediction models were developed using random forest on the training set (70%) with data on past asthma attacks, microbiome composition, serum inflammatory mediator levels, and their combinations and then tested on the rest of the population (30%). Outcomes were replicated in a subset of children with severe asthma from U-BIOPRED.
Results: Complete data were available for 154 children (SysPharmPediA = 121, U-BIOPRED = 33). In discovery, the model based on past attacks resulted in an area under the receiving characteristic curve (AUROCC) ~ 0.7. Models including six salivary bacteria or six inflammatory mediators achieved similar results. The combined model incorporating seven features, past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, TIMP-4, VEGF, and MIP-3β achieved the highest accuracy with AUROCC ~0.87. The combined model in the U-BIOPRED limited to available inflammatory mediators (VEGF), and incorporating past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, resulted in an AUROCC of 0.84.
Conclusion: Serum inflammatory mediators and salivary microbiome complement asthma attacks history for predicting future attacks. These results highlight the imperative for continued investigation into oral microbiota and its interaction with the immune system.
Keywords: 16S rRNA; asthma; biomarker; exacerbations; precision medicine; saliva.
© 2025 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
References
-
- M. W. Pijnenburg and L. Fleming, “Advances in Understanding and Reducing the Burden of Severe Asthma in Children,” Lancet Respiratory Medicine 8 (2020): 1032–1044.
-
- M. W. Pijnenburg, U. Frey, J. C. De Jongste, and S. Saglani, “Childhood Asthma: Pathogenesis and Phenotypes,” European Respiratory Journal 59 (2022): 2100731.
-
- A. H. Alizadeh Bahmani, M. I. Abdel‐Aziz, A. H. Maitland‐van der Zee, and S. J. Vijverberg, “Recent Advances in the Treatment of Childhood Asthma: A Clinical Pharmacology Perspective,” Expert Review of Clinical Pharmacology 15 (2022): 1165–1176.
-
- A. L. O'Brian, R. F. Lemanske, M. D. Evans, R. E. Gangnon, J. E. Gern, and D. J. Jackson, “Recurrent Severe Exacerbations in Early Life and Reduced Lung Function at School Age,” Journal of Allergy and Clinical Immunology 129 (2012): 1162–1164.
-
- S. Puranik, E. Forno, A. Bush, and J. C. Celedón, “Predicting Severe Asthma Exacerbations in Children,” American Journal of Respiratory and Critical Care Medicine 195 (2017): 854–859.
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous